Dianthus Therapeutics

Yahoo Finance • 27 days ago

Dianthus Therapeutics GAAP EPS of -$0.97

* Dianthus Therapeutics press release [https://seekingalpha.com/pr/20295274-dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3-financial] (DNTH [https://seekingalpha.com/symbol/DNTH]): Q3 GAAP EPS of -$0.97. *... Full story

Yahoo Finance • 27 days ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy measures at Week 13 in Phase 2 MaGic... Full story

Yahoo Finance • last month

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase 3 gMG trial planned to include QMG ≥10... Full story

Yahoo Finance • 2 months ago

Dianthus to license autoimmune disease candidate in a deal worth up $1B

[Gratitude Concept With Heart Symbol] Eoneren Dianthus Therapeutics (NASDAQ:DNTH [https://seekingalpha.com/symbol/DNTH]) announced a licensing deal worth up to $1B with Nanjing Leads Biolabs on Thursday to obtain exclusive rights to an au... Full story

Yahoo Finance • 2 months ago

Dianthus Therapeutics Enters Into Exclusive DNTH212 Licensing Deal With Nanjing Leads Biolabs

(RTTNews) - Dianthus Therapeutics, Inc. (DNTH), Thursday announced an exclusive licensing agreement with Nanjing Leads Biolabs Co., Ltd. for DNTH212, an investigational, extended half-life bifunctional fusion protein with a potential to ad... Full story

Yahoo Finance • 2 months ago

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Demonstrated superior inhibition of... Full story

Yahoo Finance • 2 months ago

Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United Healthcare

We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. Plus Therapeutics Inc. (NASDAQ:PSTV) is one of the top performers on Thursday. Shares of Plus Therapeutics soared by 39.29 percent on Thursday to finish at $0.563... Full story

Yahoo Finance • 3 months ago

Implied XBI Analyst Target Price: $142

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 3 months ago

Notable Friday Option Activity: GLW, DNTH, CROX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Corning Inc (Symbol: GLW), where a total volume of 46,563 contracts has been traded thus far today, a contract volume whi... Full story

Yahoo Finance • 3 months ago

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat se... Full story

Yahoo Finance • 3 months ago

Dianthus Therapeutics prices upsized $251M securities offering

Dianthus Therapeutics (NASDAQ:DNTH [https://seekingalpha.com/symbol/DNTH]) has priced [https://seekingalpha.com/pr/20227263-dianthus-therapeutics-inc-announces-pricing-of-upsized-251-million-underwritten-public] its recently announced and... Full story

Yahoo Finance • 3 months ago

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat se... Full story

Yahoo Finance • 3 months ago

Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential

We recently published 10 Stocks With Eye-Popping Gains; 7 Soar to Fresh Highs. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is one of the top performers on Monday. Dianthus Therapeutics soared to a new record high on Monday, as investors che... Full story

Yahoo Finance • 3 months ago

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat se... Full story

Yahoo Finance • 3 months ago

Top movers in Monday's pre-market session

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT HOUR [https://www.ch... Full story

Yahoo Finance • 3 months ago

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat se... Full story

Yahoo Finance • 5 months ago

Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best small company stocks to invest in. Stifel reaffirmed a Buy rating on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) while maintaining a price target of $52.00, citing the strength of t... Full story

Yahoo Finance • 5 months ago

Climb Bio appoints Cindy Driscoll as SVP Finance and principal financial officer

Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotech company with a market capitalization of $81 million, announced the appointment of Cindy Driscoll as Senior Vice President, Finance, effective June 17, 2025. According to InvestingPro... Full story

Yahoo Finance • 6 months ago

Dianthus Therapeutics stock maintains buy rating ahead of September trial data

Stifel reiterated a buy rating and $52.00 price target on Dianthus Therapeutics (NASDAQ:DNTH), representing significant upside from the current price of $18.22. According to InvestingPro data, analyst targets range from $34 to $84, with th... Full story

Yahoo Finance • 6 months ago

Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference

NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat seve... Full story